{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:11Z","timestamp":1787008571804,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":201,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Australian Government Research Training Program"},{"DOI":"10.13039\/501100001773","name":"UNSW Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1194940"],"award-info":[{"award-number":["1194940"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1194940"],"award-info":[{"award-number":["1194940"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2026317"],"award-info":[{"award-number":["2026317"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With transformative advances in diagnostic and therapeutic approaches in spinal muscular atrophy, the long-term neurodevelopmental outcomes of children with, or predicted to have, spinal muscular atrophy type 1 are essential to evaluate. In this single-centre cross-sectional study, development in children with\/at-risk of spinal muscular atrophy type 1, aged 1\u201366 months, was assessed using parent-reported Ages and Stages Questionnaires\u00ae (ASQ-3\u2122). Risk of autism spectrum disorder (ASD), parental distress, sociodemographic and clinical characteristics were also evaluated. Associations between exploratory variables and developmental risk were analysed within a bioecological model of health. Adaptive least absolute shrinkage and selection operator (LASSO) was used to identify variables most predictive of developmental acquisition. Thirty-seven children with spinal muscular atrophy participated (response rate: 90.2%, girls: 54.0%). Clinical characteristics varied with modality of diagnosis, survival motor neuron 2 (SMN2) copies and clinical status at initiation of survival motor neuron (SMN)-augmenting therapy. ASQ-3 scores were indicative of no\/low developmental risk in 16\/37 (43.2%), isolated gross-motor delay consistent with spinal muscular atrophy phenotype in 8\/37 (21.6%), isolated non-gross-motor delay in 3\/37 (8.1%), and global developmental delay (\u22652 domains) in 10\/37 (27.0%). The majority of children (21\/24, 87.5%) screened negative on Modified Checklist for Autism in Toddlers Revised (M-CHAT-R), indicating low risk of autism spectrum disorder. Almost one-third (32.4%) of parents reported high levels of distress. Factors associated with better developmental performance included three SMN2 copies, diagnosis through newborn bloodspot screening and clinical silent status, absence of bulbar dysfunction, higher motor function at the time of initiation of SMN-augmenting therapy, parental well-being (absence of mental health condition and no distress) and parental attainment of tertiary education. An absence of a mental health condition in parents and three SMN2 copy genotype in the child were identified as the strongest predictors of no\/low developmental risk, with odds ratios of 4.7 and 1.4, respectively. The study findings demonstrate diverse neurodevelopmental profiles in treated children with\/at-risk of spinal muscular atrophy type 1 associated with the magnitude and duration of SMN deficiency. The SMN-associated neurodevelopmental disorders may be amenable to modification by targeting bioecological factors of health. Namely, newborn screening and expedient initiation of SMN-augmenting therapies are central to targeting the neurodevelopmental window in children with\/at-risk of spinal muscular atrophy type 1. Best practice includes the incorporation of proactive developmental screening for all children with\/at-risk of spinal muscular atrophy type 1, with an integrated model of psychosocial support provided for families.<\/jats:p>","DOI":"10.1093\/braincomms\/fcaf272","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T15:05:27Z","timestamp":1753110327000},"source":"Crossref","is-referenced-by-count":10,"title":["Neurodevelopmental screening in children with early-onset spinal muscular atrophy in the treatment era: a strengths-based cohort study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9286-900X","authenticated-orcid":false,"given":"Lakshmi","family":"Balaji","sequence":"first","affiliation":[{"name":"Department of Neurology, Sydney Children's Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didu","family":"Kariyawasam","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children's Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Herbert","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children's Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Department of Physiotherapy, Sydney Children's Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo A","family":"Sampaio","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children's Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Cairns","sequence":"additional","affiliation":[{"name":"Queensland Children\u2019s Hospital , Brisbane, QLD 4101 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany C","family":"McGill","sequence":"additional","affiliation":[{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children\u2019s Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-8807","authenticated-orcid":false,"given":"Lauren","family":"Kelada","sequence":"additional","affiliation":[{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Behavioural Sciences Unit, Kids Cancer Centre, Sydney Children\u2019s Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Woolfenden","sequence":"additional","affiliation":[{"name":"Central Clinical School, Sydney Medical School, the Faculty of Medicine and Health, University of Sydney , Sydney 2006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Briggs","sequence":"additional","affiliation":[{"name":"Stats Central, Mark Wainwright Analytical Centre, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A","family":"Farrar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sydney Children's Hospital Randwick , Sydney, NSW 2031 ,","place":["Australia"]},{"name":"Discipline of Paediatrics and Child Health, School of Clinical Medicine, UNSW Medicine and Health, University of New South Wales , Sydney, NSW 2031 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"11","key":"2025082607521228000_fcaf272-B1","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J Clin Invest."},{"key":"2025082607521228000_fcaf272-B2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF00687008","article-title":"Is Werdnig-Hoffmann disease a pure lower motor neuron disorder?","volume":"65","author":"Towfighi","year":"1985","journal-title":"Acta Neuropathol"},{"key":"2025082607521228000_fcaf272-B3","first-page":"115","article-title":"Milestones for communication development in Japanese children with spinal muscular atrophy type I","volume":"14","author":"Hoshi","year":"2017","journal-title":"J Health Sci"},{"issue":"1","key":"2025082607521228000_fcaf272-B4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/10400435.2019.1586788","article-title":"Communication skills among children with spinal muscular atrophy type 1: A parent survey","volume":"33","author":"Ball","year":"2021","journal-title":"Assist Technol"},{"issue":"5","key":"2025082607521228000_fcaf272-B5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nmd.2017.01.017","article-title":"Matching pairs difficulty in children with spinal muscular atrophy type I","volume":"27","author":"Polido","year":"2017","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2025082607521228000_fcaf272-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s11689-021-09355-4","article-title":"Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1","volume":"13","author":"Zappa","year":"2021","journal-title":"J Neurodev Disord"},{"issue":"2","key":"2025082607521228000_fcaf272-B7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"2025082607521228000_fcaf272-B8","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1212\/WNL.0000000000006050","article-title":"An observational study of functional abilities in infants, children, and adults with type 1 SMA","volume":"91","author":"Pane","year":"2018","journal-title":"Neurology"},{"key":"2025082607521228000_fcaf272-B9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3233\/JND-230136","article-title":"Impaired neurodevelopment in children with 5q-SMA-2 years after newborn screening","volume":"11","author":"K\u00f6lbel","year":"2024","journal-title":"J Neuromuscul Dis"},{"key":"2025082607521228000_fcaf272-B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpn.2024.05.002","article-title":"Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life","volume":"51","author":"Steffens","year":"2024","journal-title":"Eur J Paediatr Neurol"},{"key":"2025082607521228000_fcaf272-B11","doi-asserted-by":"crossref","first-page":"17562864231154335","DOI":"10.1177\/17562864231154335","article-title":"Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy","volume":"16","author":"Ngawa","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"2025082607521228000_fcaf272-B12","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.eclinm.2021.100742","article-title":"\u201cWe needed this\u201d: Perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy","volume":"33","author":"Kariyawasam","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"3","key":"2025082607521228000_fcaf272-B13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"2025082607521228000_fcaf272-B14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/archdischild-2023-326613","article-title":"Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: A cohort study","volume":"109","author":"Buchignani","year":"2024","journal-title":"Arch Dis Child"},{"issue":"5","key":"2025082607521228000_fcaf272-B15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/dmcn.14798","article-title":"Brain, cognition, and language development in spinal muscular atrophy type 1: A scoping review","volume":"63","author":"Masson","year":"2021","journal-title":"Dev Med Child Neurol"},{"key":"2025082607521228000_fcaf272-B16","first-page":"106","volume-title":"Making human beings human: Bioecological perspectives on human development","author":"Bronfenbrenner U","year":"2005"},{"issue":"5","key":"2025082607521228000_fcaf272-B17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/dmcn.14026","article-title":"Impact of social disadvantage on cerebral palsy severity","volume":"61","author":"Woolfenden","year":"2019","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"2025082607521228000_fcaf272-B18","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamapediatrics.2022.3079","article-title":"Utility of the ages and stages questionnaire to identify developmental delay in children aged 12 to 60 months: A systematic review and meta-analysis","volume":"176","author":"Muthusamy","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2025082607521228000_fcaf272-B19","volume-title":"ASQ-3 User's guide","author":"Squires","year":"2009"},{"issue":"7","key":"2025082607521228000_fcaf272-B20","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/dmcn.15171","article-title":"Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen","volume":"64","author":"Weststrate","year":"2022","journal-title":"Dev Med Child Neurol"},{"key":"2025082607521228000_fcaf272-B21","author":"Research MIoAEaS"},{"key":"2025082607521228000_fcaf272-B22","author":"Model"},{"key":"2025082607521228000_fcaf272-B23"},{"key":"2025082607521228000_fcaf272-B24","volume-title":"Ages & stages questionnaires","author":"Squires","year":"2009"},{"key":"2025082607521228000_fcaf272-B25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/14737175.2023.2218549","article-title":"Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: A clinical perspective","volume":"23","author":"Balaji","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"2025082607521228000_fcaf272-B26","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2013","edition":"R Core Team."},{"issue":"10","key":"2025082607521228000_fcaf272-B27","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/biom12101524","article-title":"SMN is physiologically downregulated at wild-type motor nerve terminals but aggregates together with neurofilaments in SMA mouse models","volume":"12","author":"Franco-Espin","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"2025082607521228000_fcaf272-B28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.jnen.0000205144.54457.a3","article-title":"Neuronal-specific roles of the survival motor neuron protein: Evidence from survival motor neuron expression patterns in the developing human central nervous system","volume":"65","author":"Giavazzi","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"issue":"21","key":"2025082607521228000_fcaf272-B29","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1093\/hmg\/ddq340","article-title":"SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy","volume":"19","author":"Wishart","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2025082607521228000_fcaf272-B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0000000000000144","article-title":"Spectrum of neuropathophysiology in spinal muscular atrophy type I","volume":"74","author":"Harding","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"2025082607521228000_fcaf272-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.psych.031809.130730","article-title":"The development of problem solving in young children: A critical cognitive skill","volume":"62","author":"Keen","year":"2011","journal-title":"Annu Rev Psychol"},{"issue":"1","key":"2025082607521228000_fcaf272-B32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/dmcn.15640","article-title":"Social determinants of health for children with cerebral palsy and their families","volume":"66","author":"Ostojic","year":"2024","journal-title":"Dev Med Child Neurol"},{"key":"2025082607521228000_fcaf272-B33"},{"key":"2025082607521228000_fcaf272-B34"},{"issue":"2","key":"2025082607521228000_fcaf272-B35","doi-asserted-by":"crossref","first-page":"e0170171","DOI":"10.1371\/journal.pone.0170171","article-title":"ASQ3 and\/or the Bayley-III to support clinicians\u2019 decision making","volume":"12","author":"Mackin","year":"2017","journal-title":"PLoS One"},{"key":"2025082607521228000_fcaf272-B36","first-page":"101237","article-title":"A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: A registry based study","volume":"53","author":"Balaji","year":"2024","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcaf272\/63810999\/fcaf272.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/4\/fcaf272\/63810999\/fcaf272.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/7\/4\/fcaf272\/63810999\/fcaf272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T11:52:20Z","timestamp":1756209140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcaf272\/8209813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcaf272","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"fcaf272"}}